tetano
Editor, Senior Moderator
J Med Virol. 2016 Mar 7. doi: 10.1002/jmv.24516. [Epub ahead of print]
[h=1]High conservation level of CD8+ T cell immunogenic regions within an unusual H1N2 human influenza variant.[/h] Komadina N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Qui?ones-Parra SM[SUP]4,[/SUP][SUP]3[/SUP], Kedzierska K[SUP]4,[/SUP][SUP]3[/SUP], McCaw JM[SUP]4,[/SUP][SUP]5[/SUP], Kelso A[SUP]1,[/SUP][SUP]4,[/SUP][SUP]3[/SUP], Leder K[SUP]2,[/SUP][SUP]6[/SUP], McVernon J[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current seasonal influenza vaccines require regular updates due to antigenic drift causing loss of effectiveness and therefore providing little or no protection against novel influenza A subtypes. Next generation vaccines capable of eliciting CD8[SUP]+[/SUP] T cell (CTL) mediated cross-protective immunity may offer a long-term alternative strategy. However, measuring pre- and existing levels of CTL cross-protection in humans is confounded by differences in infection histories across individuals. During 2000-2003, H1N2 viruses circulated persistently in the human population for the first time and we hypothesised that the viral nucleoprotein (NP) contained novel CTL epitopes that may have contributed to the survival of the viruses. This study describes the immunogenic NP peptides of H1N1, H2N2 and H3N2 influenza viruses isolated from humans over the past century, 1918-2003, by comparing this historical dataset to reference NP peptides from H1N2 that circulated in humans during 2000-2003. Observed peptides sequences ranged from highly conserved (15%) to highly variable (12%), with variation unrelated to reported immunodominance. No unique NP peptides which were exclusive to the H1N2 viruses were noted. However, the virus had inherited the NP from a recently emerged H3N2 variant containing novel peptides, which may have assisted its persistence. Any advantage due to this novelty was subsequently lost with emergence of a newer H3N2 variant in 2003. Our approach has potential to provide insight into the population context in which influenza viruses emerge, and may help to inform immunogenic peptide selection for CTL-inducing influenza vaccines. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H1N2; cross-protection; immunogenic; influenza; peptides
PMID: 26950895 [PubMed - as supplied by publisher]
[h=1]High conservation level of CD8+ T cell immunogenic regions within an unusual H1N2 human influenza variant.[/h] Komadina N[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Qui?ones-Parra SM[SUP]4,[/SUP][SUP]3[/SUP], Kedzierska K[SUP]4,[/SUP][SUP]3[/SUP], McCaw JM[SUP]4,[/SUP][SUP]5[/SUP], Kelso A[SUP]1,[/SUP][SUP]4,[/SUP][SUP]3[/SUP], Leder K[SUP]2,[/SUP][SUP]6[/SUP], McVernon J[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current seasonal influenza vaccines require regular updates due to antigenic drift causing loss of effectiveness and therefore providing little or no protection against novel influenza A subtypes. Next generation vaccines capable of eliciting CD8[SUP]+[/SUP] T cell (CTL) mediated cross-protective immunity may offer a long-term alternative strategy. However, measuring pre- and existing levels of CTL cross-protection in humans is confounded by differences in infection histories across individuals. During 2000-2003, H1N2 viruses circulated persistently in the human population for the first time and we hypothesised that the viral nucleoprotein (NP) contained novel CTL epitopes that may have contributed to the survival of the viruses. This study describes the immunogenic NP peptides of H1N1, H2N2 and H3N2 influenza viruses isolated from humans over the past century, 1918-2003, by comparing this historical dataset to reference NP peptides from H1N2 that circulated in humans during 2000-2003. Observed peptides sequences ranged from highly conserved (15%) to highly variable (12%), with variation unrelated to reported immunodominance. No unique NP peptides which were exclusive to the H1N2 viruses were noted. However, the virus had inherited the NP from a recently emerged H3N2 variant containing novel peptides, which may have assisted its persistence. Any advantage due to this novelty was subsequently lost with emergence of a newer H3N2 variant in 2003. Our approach has potential to provide insight into the population context in which influenza viruses emerge, and may help to inform immunogenic peptide selection for CTL-inducing influenza vaccines. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] H1N2; cross-protection; immunogenic; influenza; peptides
PMID: 26950895 [PubMed - as supplied by publisher]